UBS: Slightly lowers the target price for CANSINOBIO to HKD 64, rating "Buy"
UBS released a research report stating that it has raised the revenue forecasts for CanSinoBIO for 2026 and 2027 by 22% and lowered them by 9%, respectively. The earnings per share forecasts for 2025 to 2027 have been adjusted from 0.24, 1.16, and 2.55 yuan to 0.37, 1.41, and 2.34 yuan. The target price has been lowered from HKD 66 to HKD 64, with a rating of "Buy." CanSinoBIO's management indicated that the MCV4 vaccine contributed RMB 662 million in revenue in the first three quarters of this year, a year-on-year increase of approximately 28%, mainly due to the expansion of the applicable age group and continued channel penetration. MCV4 began exporting to Indonesia in the third quarter, and the bank estimates that it will record sales of several million this year. Additionally, since its launch in mid-year, PCV13i has entered about 12 provinces, with management aiming to cover half of the provinces by the end of the year and expand to other markets next year
According to the Zhitong Finance APP, UBS has released a research report stating that it has raised the revenue forecasts for CanSinoBIO (06185) for 2026 and 2027 by 22% and lowered it by 9%, respectively. The earnings per share forecasts for 2025 to 2027 have been adjusted from 0.24, 1.16, and 2.55 yuan to 0.37, 1.41, and 2.34 yuan. The target price has been lowered from HKD 66 to HKD 64, with a rating of "Buy."
The management of CanSinoBIO stated that the MCV4 vaccine contributed RMB 662 million (the same below) in revenue in the first three quarters of this year, a year-on-year increase of approximately 28%, mainly due to the expansion of the applicable age group and continued channel penetration. MCV4 began exporting to Indonesia in the third quarter, and the bank estimates that it will record sales of several million this year. Additionally, since the launch of PCV13i in mid-year, it has entered about 12 provinces, with management aiming to cover half of the provinces by the end of the year and expand to other markets next year
